aTyr Pharma (NASDAQ:LIFE) was downgraded by Citigroup from a “neutral” rating to a “sell” rating in a research report issued on Monday, May 14th, Marketbeat Ratings reports.
Several other equities research analysts also recently weighed in on the stock. JPMorgan Chase & Co. downgraded shares of aTyr Pharma from a “neutral” rating to an “underweight” rating in a research note on Wednesday, February 14th. Zacks Investment Research raised shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a research report on Friday, March 23rd. Finally, ValuEngine raised shares of aTyr Pharma from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $3.33.
Shares of NASDAQ:LIFE opened at $0.92 on Monday. aTyr Pharma has a 12 month low of $0.80 and a 12 month high of $6.50. The company has a quick ratio of 6.90, a current ratio of 6.90 and a debt-to-equity ratio of 0.24. The stock has a market cap of $27.14 million, a price-to-earnings ratio of -0.49 and a beta of 3.49.
aTyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings results on Monday, March 19th. The biotechnology company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.04. research analysts predict that aTyr Pharma will post -1.18 EPS for the current fiscal year.
In other aTyr Pharma news, Director Paul Schimmel bought 150,000 shares of the firm’s stock in a transaction dated Friday, May 18th. The stock was bought at an average cost of $1.00 per share, with a total value of $150,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Ecor1 Capital Fund Qualified, sold 3,209,316 shares of the business’s stock in a transaction dated Wednesday, May 16th. The stock was sold at an average price of $0.93, for a total transaction of $2,984,663.88. The disclosure for this sale can be found here. Insiders own 25.00% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the stock. Sofinnova Ventures Inc purchased a new position in aTyr Pharma during the first quarter worth about $4,945,000. Dimensional Fund Advisors LP boosted its holdings in aTyr Pharma by 33.5% during the first quarter. Dimensional Fund Advisors LP now owns 114,449 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 28,699 shares during the last quarter. Deutsche Bank AG purchased a new position in aTyr Pharma during the fourth quarter worth about $199,000. Renaissance Technologies LLC boosted its holdings in aTyr Pharma by 143.2% during the fourth quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock worth $978,000 after purchasing an additional 164,500 shares during the last quarter. Finally, Artal Group S.A. boosted its holdings in aTyr Pharma by 100.0% during the fourth quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock worth $1,750,000 after purchasing an additional 250,000 shares during the last quarter. Institutional investors and hedge funds own 66.25% of the company’s stock.
aTyr Pharma Company Profile
aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company’s therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.
Receive News & Ratings for aTyr Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for aTyr Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.